Parameter | Non-progressive | Progressive group (n = 27) | p value |
---|---|---|---|
group (n = 71) | |||
Gender (% male) | 38 (53.52%) | 12 (44.44%) | 0.422a |
Age (yrs) | 61.45 ± 12.99 | 67.22 ± 8.93 | 0.023b |
BMI (kg/m2) | 24.32 ± 3.09 | 23.27 ± 3.39 | 0.143c |
mIOP (mmHg) | 15.30 ± 2.68 | 15.39 ± 3.71 | 0.900c |
aMAP (mmHg) | 94.00 ± 8.43 | 90.81 ± 9.28 | 0.107c |
Visual field MD (dB) | −7.44 ± 5.24 | −6.71 ± 5.98 | 0.233b |
RNFL (μm) | 76.54 ± 12.93 | 76.56 ± 14.16 | 0.995c |
Presenting visual acuity (logMAR) | 0.23 ± 0.20 | 0.28 ± 0.20 | 0.222b |
SE (D) | −0.89 ± 3.14 | 0.06 ± 2.74 | 0.117b |
AL (mm) | 24.19 ± 1.72 | 23.86 ± 1.05 | 0.520b |
CCT (μm) | 539.07 ± 30.18 | 540.89 ± 28.84 | 0.788c |
No. of visual field (MD) | Â | Â | 0.744 a |
 MD ≥ −12 dB [n (%)] | 67 (94.40%) | 25 (92.60%) |  |
 MD < −12 dB [n (%)] | 4 (5.60%) | 2 (7.40%) |  |
IOP-lowering medications | Â | Â | 0.228a |
 Non-medications [n (%)] | 52 (73.20%) | 17 (63.00%) |  |
 One medication [n (%)] | 17 (23.90%) | 9 (33.30%) |  |
 Two medications [n (%)] | 2 (2.80%) | 0 (0.00%) |  |
 Three medications [n (%)] | 0 (0.00%) | 1 (3.70%) |  |
Self-reported hypertension [n (%)] | 21 (29.6%) | 6 (22.2%) | 0.467a |
Self-reported diabetes [n (%)] | 30 (42.3%) | 8 (29.6%) | 0.252a |
Total days of PA measurement | 6.82 ± 0.39 | 6.70 ± 0.47 | 0.225b |
Follow-up period (months) | 41 ± 10.89 | 31.11 ± 10.32 | < 0.001b |
Number of Follow-ups (n) | 11.20 ± 3.97 | 6.85 ± 2.58 | < 0.001b |